Syed Rahman, MD
Hospital ResidentCards
About
Research
Publications
2025
Advancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle Invasive Bladder Cancer
Smani S, DuBois J, Zhao K, Sutherland R, Rahman S, Humphrey P, Hesse D, Tan W, Martin D, Lokeshwar S, Ghali F. Advancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle Invasive Bladder Cancer. Current Oncology Reports 2025, 1-11. PMID: 39976835, DOI: 10.1007/s11912-025-01645-7.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerInvasive bladder cancerBladder cancerRisk stratificationBCG-unresponsive NMIBCEarly radical cystectomyTERT promoter mutationsHigh-risk casesLong-term outcomesNadofaragene firadenovecIntravesical therapyTransurethral resectionRadical cystectomyTreatment paradigmStratified careReduce overtreatmentProgression riskIntegration of biomarkersPromoter mutationsClinical trialsTherapeutic strategiesReviewThis reviewPersonalized treatmentAdverse effectsClinical careModeling survival outcomes of KEYNOTE-564 with standard of care control arm treatment: A simulation study.
Ghali F, Rahman S, James S. Modeling survival outcomes of KEYNOTE-564 with standard of care control arm treatment: A simulation study. Journal Of Clinical Oncology 2025, 43: 517-517. DOI: 10.1200/jco.2025.43.5_suppl.517.Peer-Reviewed Original ResearchStandard of careKEYNOTE-564KEYNOTE-426Renal cell carcinomaCheckpoint inhibitorsUnadjusted hazard ratioOverall survivalControl armHazard ratioPatient-level survival dataFirst-line settingImproved overall survivalProportion of patientsKaplan-Meier plotsMortality riskSurvival parametersControl group patientsOne-year mortality riskCell carcinomaFirst-lineSurvival outcomesControl patientsGroup patientsSurvival curvesArm treatment
2024
Management strategies for radio-recurrent prostate cancer: a comprehensive review
Rahman S, Kim H, Webb L, Diaz G, Leapman M, Sprenkle P, Brito J, Renzulli J, Martin T, Kenney P, Kim I. Management strategies for radio-recurrent prostate cancer: a comprehensive review. Translational Cancer Research 2024, 0: 0-0. PMID: 39697737, PMCID: PMC11651831, DOI: 10.21037/tcr-24-245.Peer-Reviewed Original ResearchDiagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy
Press B, Lokeshwar S, Webb L, Khajir G, Smani S, Olawoyin O, Gardezi M, Rahman S, Leapman M, Sprenkle P. Diagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 1168-1176. PMID: 39465014, PMCID: PMC11502073, DOI: 10.37349/etat.2024.00269.Peer-Reviewed Original ResearchProstate Health IndexMRI-ultrasound fusion targeted biopsyClinically significant prostate cancerFusion targeted biopsyPI-RADS 1Gleason grade groupMagnetic resonance imagingPhi densityPI-RADSProstate specific-antigenProstate biopsyImproved detection of clinically significant prostate cancerDetection of clinically significant prostate cancerPHI testingProstate health index densityElevated prostate-specific antigenMRI-ultrasound fusionProstate Imaging ReportingSignificant prostate cancerProstate-specific antigenSelection of patientsDetection of PCaReceiver operating characteristic curveCombination of magnetic resonance imagingMultivariate logistic regressionClassification and Risk Factors for Surgical Site Infections in Radical Cystectomy: A 16-Year Analysis
Lokeshwar S, Choksi A, Smani S, Ip K, Javier-DesLoges J, Rahman S, Leapman M, Martin T, Hesse D. Classification and Risk Factors for Surgical Site Infections in Radical Cystectomy: A 16-Year Analysis. Surgical Infections 2024, 25: 580-585. PMID: 38959160, PMCID: PMC11807858, DOI: 10.1089/sur.2024.107.Peer-Reviewed Original ResearchSurgical site infectionBody mass indexRadical cystectomyCenters for Disease Control and PreventionIndependent risk factorLength of stayRisk factorsAntibiotic agentsSite infectionCenters for Disease Control and Prevention classificationRisk factors of surgical site infectionFactors associated with surgical site infectionFactors of surgical site infectionPredictive of surgical site infectionDeep incision surgical site infectionSurgical site infection predictorsOdds ratioTreatment of surgical site infectionsDeep surgical site infectionPeri-operative characteristicsPeri-operative morbidityCharlson Comorbidity IndexLogistic regression analysisSuperficial incisionalDisease Control and PreventionHF01-10 UROLOGIC EDUCATION AT THE TURN OF THE 20TH CENTURY: A STUDENT’S PERSPECTIVE
Lokeshwar S, Shaheen D, Choksi A, Patel M, Rahman S, Martin T, Hesse D, Leapman M. HF01-10 UROLOGIC EDUCATION AT THE TURN OF THE 20TH CENTURY: A STUDENT’S PERSPECTIVE. Journal Of Urology 2024, 211: e282. DOI: 10.1097/01.ju.0001008828.35887.de.10.Peer-Reviewed Original ResearchMP31-04 HOW DO 5-ALPHA-REDUCTASE INHIBITORS CHANGE PSA DENSITY IN PATIENTS ON ACTIVE SURVEILLANCE?
Webb L, Diaz G, Rahman S, Khajir G, Sprenkle P. MP31-04 HOW DO 5-ALPHA-REDUCTASE INHIBITORS CHANGE PSA DENSITY IN PATIENTS ON ACTIVE SURVEILLANCE? Journal Of Urology 2024, 211: e504. DOI: 10.1097/01.ju.0001008936.35187.0b.04.Peer-Reviewed Original ResearchMP75-10 NOCTURIA ACROSS THE HEART FAILURE CONTINUUM: RESULTS FROM AN OUTPATIENT UROLOGY POPULATION
Yim S, Fang A, Ksido L, Morris M, Glover B, Rahman S, Weiss J, Tologonova G, Everaert K, DeBacker T, Roberts M, Salciccioli L, Lazar J, Monaghan T. MP75-10 NOCTURIA ACROSS THE HEART FAILURE CONTINUUM: RESULTS FROM AN OUTPATIENT UROLOGY POPULATION. Journal Of Urology 2024, 211: e1235. DOI: 10.1097/01.ju.0001008676.21744.5f.10.Peer-Reviewed Original ResearchArea Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma
Rahman S, Long J, Westvold S, Leapman M, Spees L, Hurwitz M, McManus H, Gross C, Wheeler S, Dinan M. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open 2024, 7: e248747. PMID: 38687479, PMCID: PMC11061765, DOI: 10.1001/jamanetworkopen.2024.8747.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaArea-level measuresRenal cell carcinomaPatient-level factorsSystemic therapyEthnic disparitiesRelative risk ratiosSocially vulnerable areasCell carcinomaMeasures of social vulnerabilityMedicare beneficiariesCohort studyFee-for-service Medicare Parts AOdds ratioReceipt of systemic therapyLogistic regressionArea-level characteristicsAssociated with lack of treatmentNon-Hispanic blacksRetrospective cohort studyIndividual-level demographicsNon-Hispanic whitesAssociated with disparitiesUS Medicare beneficiariesMeasures of disadvantagePrevalence of Sleep CALM nocturia factors in a male veteran population
Monaghan T, Fang A, Ksido L, Hachicho C, Muneeb M, Rahman S, Kheir G, Lazar J, Everaert K, Wein A, Weiss J. Prevalence of Sleep CALM nocturia factors in a male veteran population. Neurourology And Urodynamics 2024, 43: 1127-1133. PMID: 38511613, DOI: 10.1002/nau.25410.Peer-Reviewed Original ResearchAssociated with advanced ageFrequency-volume chartUrinary tract dysfunctionSignificant diagnostic challengeMedical history dataMale veteran populationGenitourinary abnormalitiesNocturnal voidsUrinary tractDiagnostic challengeConsensus guidelinesHost of conditionsNocturiaRetrospective analysisUrology settingAdvanced agePatient populationMultifactorial conditionReal-world practiceSleep disordersNocturia patientsDifferential effects of ageEffects of ageMedication useSleep
News
News
- January 16, 2025
Yale Urology Research [Q4: October-December 2024]
- December 16, 2024
Yale Pediatric Urology Visiting Professor Day
- October 30, 2024
Yale Urology Research [Q3: July-September 2024]
- July 31, 2024
Yale Urology Research [Q2: April-June 2024]
Get In Touch
Contacts
Email